Payment overview · 2025
General Payments
$52.79
3 reported records · 3 companies
Healthcare provider profile · identity verified
David J Bearss, M.D.
Allopathic & Osteopathic Physicians|Pediatrics · SALISBURY, NC · NPI 1063408235
Verified facts
What the public records show
CMS Open Payments records show David J Bearss, M.D. received $52.79 in general payments during 2025 across 3 reported records.
Dexcom, Inc. accounted for 43.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic, Rybelsus.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 180 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $22.78 | 43.1% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $15.12 | 28.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.89 | 28.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $52.79 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $22.78 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $15.12 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $15.12 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $14.89 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.89 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 180 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 77 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
77 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
180 | 37 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
29 | 28 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 582 | 157 |
| Omeprazole | Omeprazole | 561 | 144 |
| Levothyroxine Sodium | Levothyroxine Sodium | 540 | 129 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 536 | 146 |
| Atorvastatin Calcium | Atorvastatin Calcium | 489 | 134 |
| Gabapentin | Gabapentin | 377 | 87 |
| Losartan Potassium | Losartan Potassium | 347 | 94 |
| Lisinopril | Lisinopril | 330 | 84 |
| Carvedilol | Carvedilol | 283 | 70 |
| Simvastatin | Simvastatin | 260 | 62 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 255 | 64 |
| Metformin Hcl | Metformin Hcl | 255 | 61 |
| Metformin Hcl Er | Metformin Hcl | 238 | 62 |
| Tamsulosin Hcl | Tamsulosin Hcl | 237 | 77 |
| Potassium Chloride | Potassium Chloride | 228 | 51 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 225 | 40 |
| Tizanidine Hcl | Tizanidine Hcl | 220 | 54 |
| Pantoprazole Sodium | Pantoprazole Sodium | 211 | 68 |
| Fluticasone Propionate | Fluticasone Propionate | 209 | 69 |
| Furosemide | Furosemide | 205 | 58 |
| Metoprolol Succinate | Metoprolol Succinate | 205 | 59 |
| Montelukast Sodium | Montelukast Sodium | 194 | 48 |
| Clonazepam | Clonazepam | 182 | 36 |
| Eliquis | Apixaban | 180 | 37 |
| Clopidogrel | Clopidogrel Bisulfate | 166 | 44 |
| Tramadol Hcl | Tramadol Hcl | 163 | 49 |
| Zolpidem Tartrate | Zolpidem Tartrate | 163 | 33 |
| Ezetimibe | Ezetimibe | 162 | 48 |
| Jardiance | Empagliflozin | 157 | 30 |
| Duloxetine Hcl | Duloxetine Hcl | 155 | 34 |
| Allopurinol | Allopurinol | 149 | 40 |
| Famotidine | Famotidine | 148 | 45 |
| Glimepiride | Glimepiride | 147 | 37 |
| Hydrochlorothiazide | Hydrochlorothiazide | 143 | 37 |
| Trazodone Hcl | Trazodone Hcl | 127 | 32 |
| Pravastatin Sodium | Pravastatin Sodium | 124 | 36 |
| Metoprolol Tartrate | Metoprolol Tartrate | 123 | 35 |
| Prednisone | Prednisone | 121 | 83 |
| Pregabalin | Pregabalin | 118 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 115 | 32 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 108 | 82 |
| Telmisartan | Telmisartan | 108 | 39 |
| Sertraline Hcl | Sertraline Hcl | 99 | 28 |
| Xarelto | Rivaroxaban | 99 | 14 |
| Oxycodone Hcl | Oxycodone Hcl | 98 | 26 |
| Spironolactone | Spironolactone | 91 | 23 |
| Meloxicam | Meloxicam | 89 | 26 |
| Escitalopram Oxalate | Escitalopram Oxalate | 88 | 18 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 88 | 18 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 84 | 16 |
| Ibuprofen | Ibuprofen | 81 | 18 |
| Lorazepam | Lorazepam | 77 | 20 |
| Ozempic | Semaglutide | 77 | 12 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 77 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 75 | 17 |
| Alprazolam | Alprazolam | 73 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 72 | 20 |
| Fenofibrate | Fenofibrate | 70 | 18 |
| Baclofen | Baclofen | 68 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 66 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 66 | 17 |
| Celecoxib | Celecoxib | 64 | 17 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 64 | 20 |
| Meclizine Hcl | Meclizine Hcl | 63 | 20 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 59 | 17 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 58 | 18 |
| Levetiracetam | Levetiracetam | 58 | 12 |
| Diazepam | Diazepam | 55 | 15 |
| Symbicort | Budesonide/Formoterol Fumarate | 55 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 55 | 13 |
| Valsartan | Valsartan | 53 | 18 |
| Cefdinir | Cefdinir | 51 | 43 |
| Myrbetriq | Mirabegron | 51 | suppressed |
| Finasteride | Finasteride | 50 | 14 |
| Nystatin | Nystatin | 49 | 20 |
| Promethazine Hcl | Promethazine Hcl | 49 | suppressed |
| Linzess | Linaclotide | 48 | 15 |
| Mometasone Furoate | Mometasone Furoate | 47 | 18 |
| Mupirocin | Mupirocin | 47 | 18 |
| Ondansetron Odt | Ondansetron | 47 | 14 |
| Breo Ellipta | Fluticasone/Vilanterol | 46 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 46 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 46 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 46 | suppressed |
| Naproxen | Naproxen | 45 | 15 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 45 | 13 |
| Mirtazapine | Mirtazapine | 44 | 13 |
| Colchicine | Colchicine | 42 | 14 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 41 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 41 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 41 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 40 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 40 | 12 |
| Ventolin Hfa | Albuterol Sulfate | 39 | 14 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 38 | 13 |
| Nitroglycerin | Nitroglycerin | 38 | 16 |
| Entresto | Sacubitril/Valsartan | 37 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 37 | 30 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 37 | 22 |
| Trulicity | Dulaglutide | 37 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 36 | suppressed |
| Chlorthalidone | Chlorthalidone | 35 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 35 | suppressed |
| Levofloxacin | Levofloxacin | 35 | 25 |
| Warfarin Sodium | Warfarin Sodium | 34 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 33 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 32 | 24 |
| Quetiapine Fumarate | Quetiapine Fumarate | 32 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 31 | 18 |
| Tresiba Flextouch U-200 | Insulin Degludec | 30 | suppressed |
| Carisoprodol | Carisoprodol | 29 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 29 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 29 | 28 |
| Synthroid | Levothyroxine Sodium | 29 | suppressed |
| Cephalexin | Cephalexin | 28 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 28 | suppressed |
| Methotrexate | Methotrexate Sodium | 28 | suppressed |
| Ramipril | Ramipril | 28 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 28 | 15 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 27 | suppressed |
| Glipizide | Glipizide | 27 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 27 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 27 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 27 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 26 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 26 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 26 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 26 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 26 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 26 | suppressed |
| Amoxicillin | Amoxicillin | 25 | 20 |
| Ranolazine Er | Ranolazine | 25 | suppressed |
| Torsemide | Torsemide | 24 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 23 | suppressed |
| Januvia | Sitagliptin Phosphate | 23 | suppressed |
| Hydrocortisone | Hydrocortisone | 22 | suppressed |
| Methocarbamol | Methocarbamol | 22 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 22 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 21 | suppressed |
| Atenolol | Atenolol | 21 | suppressed |
| Fluconazole | Fluconazole | 21 | 17 |
| Lovastatin | Lovastatin | 21 | suppressed |
| Methadone Hcl | Methadone Hcl | 21 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 21 | suppressed |
| Sucralfate | Sucralfate | 21 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 20 | suppressed |
| Invokana | Canagliflozin | 20 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 19 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 19 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 19 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 18 | suppressed |
| Loperamide | Loperamide Hcl | 18 | suppressed |
| Olanzapine | Olanzapine | 18 | suppressed |
| Topiramate | Topiramate | 18 | suppressed |
| Bupropion Xl | Bupropion Hcl | 17 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 17 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 17 | suppressed |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Mounjaro | Tirzepatide | 16 | suppressed |
| Rybelsus | Semaglutide | 16 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Azithromycin | Azithromycin | 15 | 15 |
| Levemir Flexpen | Insulin Detemir | 15 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 15 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 14 | 13 |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | 11 |
| Irbesartan | Irbesartan | 13 | suppressed |
| Latanoprost | Latanoprost | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Timolol Maleate | Timolol Maleate | 13 | suppressed |
| Armodafinil | Armodafinil | 12 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Niacin Er | Niacin | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Amantadine | Amantadine Hcl | 11 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 11 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 11 | suppressed |
| Epinephrine | Epinephrine | 11 | suppressed |
| Fluocinonide | Fluocinonide | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 11 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 11 | suppressed |
| Xtampza Er | Oxycodone Myristate | 11 | suppressed |
| Zaleplon | Zaleplon | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $52.79 · 3 records | Dexcom, Inc. | Dexcom G6 Transmitter, ELIQUIS, NURTEC ODT, Ozempic, Rybelsus | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error